Abstract: A soft magnetic alloy includes a main component of (Fe(1?(?+?))X1?X2?)(1?(a+b+c+d+e))MaBbPcSidCe. X1 is one or more of Co and Ni. X2 is one or more of Al, Mn, Ag, Zn, Sn, As, Sb, Cu, Cr, Bi, N, O, and rare earth elements. M is one or more of Nb, Hf, Zr, Ta, Mo, W, and V. 0.020?a?0.14 is satisfied. 0.020<b?0.20 is satisfied. 0?d?0.060 is satisfied. ??0 is satisfied. ??0 is satisfied. 0??+??0.50 is satisfied. c and e are within a predetermined range. The soft magnetic alloy has a nanohetero structure or a structure of Fe based nanocrystallines.

Abstract: A soft magnetic alloy powder comprises a component having a compositional formula ((Fe(1?(?+?))Co?Ni?)(1??)X1?)(1?(a+b+c+d+e))BaPbSicCdCre in atomic ratio. X1 comprises at least one selected from specific elements. Values of a, b, c, d, e, ?, ?, and ? of the compositional formula satisfy specific ranges. The soft magnetic alloy powder comprises soft magnetic alloy particles including soft magnetic alloy particles having a particle size of (0.95×D90) or more and (1.05×D90) or less. An average Wadell's circularity of the soft magnetic alloy particles having the particle size of (0.95×D90) or more and (1.05×D90) or less is 0.75 or more. A variance of Wadell's circularity of the soft magnetic alloy particles having the particle size of (0.95×D90) or more and (1.05×D90) or less is 0.035 or less.

Abstract: A soft magnetic alloy powder comprises first particles to fifth particles, each having a particle size within a specific range. Among the first particles to the fifth particles, nth particles have an average particle size xn (?m), an average circularity yn, and a variance zn of circularity, where nth is any ordinal number from first to fifth. Points (xn, yn) (n=1 to 5) plotted in an xy plane define an approximate straight line having a slope “my” of ?0.0030 or more. Points (xn, zn) (n=1 to 5) plotted in an xz plane define an approximate straight line having a slope “mz” of 0.00050 or less.

Abstract: The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba/F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC/Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications.

Abstract: A fuel vapor processing apparatus may include a first canister and a second canister each having an adsorbent disposed therein. The second canister may include a first passage and a second passage each communicating between the first canister and an atmosphere. The first passage may be configured as an adsorption passage having the adsorbent disposed therein. The second passage may be configured as an air passage through which air flows. A control device may control flow of the air through the air passage. A heating device may heat the air flowing through the air passage. The air passage may be arranged so that the adsorbent of the adsorption chamber is heated by heat of the air that is heated by the heating device and flows through the air passage.

Abstract: The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba/F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC/Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications.

Abstract: The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba/F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC/Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications.

Abstract: A fuel vapor processing apparatus may include a first canister and a second canister each having an adsorbent disposed therein. The second canister may include a first passage and a second passage each communicating between the first canister and an atmosphere. The first passage may be configured as an adsorption passage having the adsorbent disposed therein. The second passage may be configured as an air passage through which air flows. A control device may control flow of the air through the air passage. A heating device may heat the air flowing through the air passage. The air passage may be arranged so that the adsorbent of the adsorption chamber is heated by heat of the air that is heated by the heating device and flows through the air passage.

Abstract: A canister includes a first fuel vapor adsorption device and a second fuel vapor adsorption device. The second fuel vapor adsorption device can adsorb a part of fuel vapor that still remains in a gas after desorption by the first fuel vapor adsorption device. The second fuel vapor adsorption device includes a first passage containing a fuel vapor adsorption material and a second passage containing no fuel vapor adsorption material. The first passage and the second passage allow the gas to flow therethrough. A gas introduction device allows the fuel vapor to flow from the second passage into the first passage.

Abstract: An adsorbent canister has a housing defining an adsorption chamber therein, an adsorbent filled in the adsorption chamber, and a honeycomb core. The honeycomb core is made from a material having a higher thermal conductivity than the adsorbent, defines therein a plurality of cells passing through the honeycomb core and is disposed in the adsorption chamber. The adsorbent canister can further have a heater for heating the honeycomb core or the honeycomb core can be made from a material, which produce heat when current is applied.

Abstract: An adsorbent canister has a housing defining an adsorption chamber therein, an adsorbent filled in the adsorption chamber, and a honeycomb core. The honeycomb core is made from a material having a higher thermal conductivity than the adsorbent, defines therein a plurality of cells passing through the honeycomb core and is disposed in the adsorption chamber. The adsorbent canister can further have a heater for heating the honeycomb core or the honeycomb core can be made from a material, which produce heat when current is applied.

Abstract: A fuel vapor processor has a fuel tank, a canister, a recovery pipe, a fuel pump, a negative pressure generator, a pressure regulator, a fuel intake pipe and a fuel intake regulator. The vapor pipe leads the fuel vapor generated in the fuel tank into the canister for trapping the fuel vapor. The recovery pipe connects the fuel tank and the canister for recovering the fuel vapor trapped in the canister into the fuel tank. The fuel intake pipe directly connects the fuel pump provided in the fuel tank with the negative pressure generator for leading fuel to the negative pressure generator. The negative pressure generator generates negative pressure depending on an amount of fuel supplied to the negative pressure generator from the fuel pump. The fuel vapor trapped in the canister is recovered to the fuel tank through the recovery pipe due to the negative pressure. The pressure regulator is connected with the fuel pump for returning excess fuel discharged from the fuel pump into the fuel tank.

Abstract: The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba/F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.

Abstract: A canister has a canister case, an adsorbent chamber defined in the canister case, and an adsorbent disposed in the adsorbent chamber. The adsorbent can adsorb fuel vapor as the fuel vapor flows through the adsorbent chamber in a first direction. On the other hand, the adsorbent allows desorption of fuel vapor as air flows through the adsorbent in a second direction opposite to the first direction. The adsorbent chamber includes a first adsorbent chamber and a second absorbent chamber communicating with each other. The first adsorbent chamber is disposed on an upstream side of the second adsorbent chamber with respect to the first direction. The adsorbent includes a first adsorbent disposed in the first adsorbent chamber and a second adsorbent disposed in the second adsorbent chamber. A desorption promoting device is disposed in the second adsorbent chamber and can promote desorption of fuel vapor from the second adsorbent.

Abstract: An adsorbent canister has a housing defining an adsorption chamber therein, an adsorbent filled in the adsorption chamber, and a honeycomb core. The honeycomb core is made from a material having a higher thermal conductivity than the adsorbent, defines therein a plurality of cells passing through the honeycomb core and is disposed in the adsorption chamber. The adsorbent canister can further have a heater for heating the honeycomb core or the honeycomb core can be made from a material, which produce heat when current is applied.

Abstract: A canister includes a first fuel vapor adsorption device and a second fuel vapor adsorption device. The second fuel vapor adsorption device can adsorb a part of fuel vapor that still remains in a gas after desorption by the first fuel vapor adsorption device. The second fuel vapor adsorption device includes a first passage containing a fuel vapor adsorption material and a second passage containing no fuel vapor adsorption material. The first passage and the second passage allow the gas to flow therethrough. A gas introduction device allows the fuel vapor to flow from the second passage into the first passage.

Abstract: The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba/F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.

Abstract: A fuel vapor processor has a fuel tank, a canister, a recovery pipe, a fuel pump, a negative pressure generator, a pressure regulator, a fuel intake pipe and a fuel intake regulator. The vapor pipe leads the fuel vapor generated in the fuel tank into the canister for trapping the fuel vapor. The recovery pipe connects the fuel tank and the canister for recovering the fuel vapor trapped in the canister into the fuel tank. The fuel intake pipe directly connects the fuel pump provided in the fuel tank with the negative pressure generator for leading fuel to the negative pressure generator. The negative pressure generator generates negative pressure depending on an amount of fuel supplied to the negative pressure generator from the fuel pump. The fuel vapor trapped in the canister is recovered to the fuel tank through the recovery pipe due to the negative pressure. The pressure regulator is connected with the fuel pump for returning excess fuel discharged from the fuel pump into the fuel tank.

Abstract: A movable valve 131 is movably supported by a support plate 135 within a valve body having a gas injection nozzle 129. The valve body consists of a plurality of members 103, 105, 107, 109, 127. Impermeable joints 147a, 147b, 147c are formed between the members. The support plate 135 includes a plurality of elastically deformable support portions each having an inner radial connection, an outer radial connection and a circumferential connection. The support portions are phase adjusted to radial fluid passages 131h formed in the movable valve 113.

Abstract: The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba/F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC/Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications.